G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Neuropathic Pain and Cardiovascular Research

G-1 (CAS 881639-98-1) has emerged as a pivotal chemical agonist for GPR30 (GPER1), enabling new frontiers in research on estrogen receptor independent signaling, neuropathic pain, and cardiac physiology. This article delivers an advanced, integrative analysis of G-1’s molecular pharmacology, distinct mechanistic pathways, and transformative potential in preclinical research—emphasizing scientific nuances and translational relevance beyond prior overviews.

Introduction

G protein-coupled estrogen receptor 30 (GPR30/GPER1) is an endoplasmic reticulum membrane receptor that mediates non-classical estrogen signaling, influencing cellular processes ranging from calcium mobilization to PI3K/Akt/mTOR pathway activation. Unlike classical estrogen receptors (ERα and ERβ), GPR30 triggers rapid, membrane-initiated events and participates in diverse physiological and pathological contexts—including cardiovascular health, cancer biology, and neuropathic pain modulation. G-1 (CAS 881639-98-1), a selective GPR30 agonist supplied by APExBIO, offers unrivaled specificity, nanomolar potency, and chemical suitability for dissecting GPR30-mediated signaling in vitro and in vivo.

Mechanism of Action of G-1: A Paradigm of Selective GPR30 Activation

Binding and Selectivity

G-1 binds GPR30 with a reported Ki of ~11 nM and demonstrates negligible affinity for ERα and ERβ, even at micromolar concentrations. As a DMSO soluble small molecule (solubility ≥41.2 mg/mL), G-1’s crystalline purity and pharmacological selectivity make it the gold standard GPR30 selective ligand for mechanistic and translational research.

Intracellular Signaling Cascade

Upon GPR30 activation by G-1, two key signaling events dominate:

• Intracellular Calcium Elevation: G-1 induces rapid elevation of cytosolic Ca²⁺ (EC₅₀ = 2 nM), a hallmark of G protein-coupled estrogen receptor agonist activity. This Ca²⁺ influx governs downstream gene expression, metabolic activity, and cell motility.
• PI3K-Dependent PIP3 Nuclear Accumulation: G-1 triggers nuclear accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) through PI3K activation, modulating the PI3K/Akt/mTOR signaling pathway. This mechanism underpins GPR30’s role in cellular proliferation, survival, and migration.

Functional Outcomes: Cellular and Physiological Impact

• Breast Cancer Cell Migration Inhibition: In vitro, G-1 inhibits migration of SKBr3 and MCF7 breast cancer cells (IC₅₀ = 0.7–1.6 nM), selectively activating GPR30 in cells co-expressing estrogen receptors and providing a tool for breast cancer research and chemoprevention studies.
• Cardiac Fibrosis Attenuation and Heart Failure Models: Chronic G-1 administration (120 μg/kg, 14 days) in ovariectomized, heart failure model rats reduces brain natriuretic peptide, inhibits cardiac fibrosis, and normalizes β1/β2-adrenergic receptor expression—validating G-1 as a cardioprotective agent in preclinical cardiovascular research.

G-1 in Neuropathic Pain Modulation: Insights from Recent Research

While prior articles have focused on G-1’s role in rapid estrogen signaling and classical cardiovascular or oncology models, recent advances uncover its critical function in neuropathic pain circuitry. A landmark study (Chen, Wu, Xie et al., eLife 2024) demonstrated that GPR30 expression in spinal cholecystokinin-positive (CCK+) neurons is upregulated following nerve injury. Inhibition of GPR30 in these neurons reverses mechanical allodynia and mitigates pain hypersensitivity.

Mechanistically, GPR30 facilitates AMPA receptor-mediated excitatory synaptic transmission in the spinal dorsal horn, integrating direct projections from the primary somatosensory cortex. Chemogenetic modulation of these pathways confirms that GPR30 is essential for neuropathic pain manifestation and represents a promising therapeutic target. This unique application of G-1 as a research tool for dissecting spinal cord circuits in neuropathic pain distinguishes this article from existing GPR30 agonist content, which traditionally centers on cardiovascular or cancer models.

Comparative Analysis with Alternative Tools and Approaches

Many researchers rely on ERα/ERβ agonists, broad-spectrum estrogen analogs, or genetic knockout models to study estrogen signaling. These approaches, while informative, lack the receptor specificity and rapid, non-genomic selectivity offered by G-1. For example, prior reviews emphasize G-1’s nanomolar potency and minimal off-target effects, framing it as a benchmark for non-classical estrogen pathway research. However, this article extends that discussion by integrating G-1’s role in the molecular neurobiology of pain, a dimension previously underexplored.

Furthermore, workflow optimization guides such as cell assay optimization articles highlight G-1’s reliability in viability and cytotoxicity assays but do not address its mechanistic impact on neural circuits or translational pain models. Here, we provide a deeper mechanistic analysis, empowering researchers to leverage G-1 for sophisticated neurophysiological investigations.

Advanced Applications: Cardiovascular, Oncology, and Endocrine Research

Cardiovascular Research and Heart Failure Models

G-1’s ability to attenuate cardiac fibrosis and modulate β-adrenergic receptor expression positions it as a premier tool for studying heart failure animal models and GPR30-mediated cardioprotection. In contrast to content such as benchmarking reports that focus on translational endpoints, our analysis connects these endpoints to upstream PI3K signaling and receptor-specific interventions, providing a roadmap for mechanistic explorations and therapeutic hypothesis generation.

Breast Cancer Research and Cell Migration

G-1’s inhibition of breast cancer cell migration through GPR30 activation enables precise dissection of estrogen receptor independent signaling, vital for oncology models where ER status is heterogeneous. This positions G-1 as an essential GPR30 agonist for chemoprevention and metastatic research. Prior summaries often catalog endpoint data; here, we contextualize these findings within the broader landscape of PI3K/Akt/mTOR pathway modulation and genomic versus non-genomic estrogen effects.

Emerging Dimensions: GPR30 in Neuropathic Pain and Endocrine Modulation

The referenced study (Chen, Wu, Xie et al., 2024) reveals a new avenue for G-1: as a molecular probe for spinal GPR30 function in neuropathic pain models. By elucidating the circuit-level integration between the somatosensory cortex and spinal CCK+ neurons, G-1 enables unprecedented dissection of pain mechanisms, laying the groundwork for next-generation analgesic research.

Additionally, G-1’s selectivity for GPR30 enables studies in endocrine research, allowing researchers to differentiate rapid, GPR30-mediated signaling from classical, nuclear estrogen receptor pathways—illuminating physiological and pathological processes in metabolic, reproductive, and neurological systems.

Experimental Considerations and Best Practices

• Formulation: G-1 is insoluble in water and ethanol but highly soluble in DMSO. For experimental use, prepare stock solutions at >10 mM in DMSO, using warming and ultrasonic treatment as needed.
• Storage: Store stock solutions at -20°C and use promptly to prevent degradation. Shipping from APExBIO utilizes blue ice for temperature-sensitive handling.
• Controls: Given G-1's selectivity, include both ERα/ERβ antagonists and vehicle controls to delineate GPR30-specific effects.
• Model Selection: For in vivo work, validated protocols in ovariectomized and heart failure animal models, as well as neuropathic pain paradigms, maximize the translational value of G-1 studies.

Conclusion and Future Outlook

G-1 (CAS 881639-98-1) stands at the intersection of molecular pharmacology and translational research as a selective GPR30 agonist, offering unique capabilities for dissecting estrogen receptor independent signaling, cardiovascular physiology, cancer cell migration, and—critically—neuropathic pain pathways. By bridging the mechanistic gap between receptor activation and physiological endpoints, G-1 enables both hypothesis-driven discovery and translational proof-of-concept studies.

This article advances the field by integrating new findings on GPR30’s role in spinal pain circuitry and by mapping intricate signaling pathways downstream of G-1, extending beyond the scope of existing product reviews and application notes. As the neuroscience and cardiovascular communities continue to explore GPR30 as a therapeutic target, G-1 supplied by APExBIO will remain an indispensable research tool for next-generation biomedical innovation.

For further technical details, purchasing information, and protocols, visit the G-1 (CAS 881639-98-1) product page.